1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Sage Burned By Short Report

 
• By Lisa LaMotta

Sage Therapeutics faced the wrath of finicky investors on March 23 as its shares dropped more 20% in early morning trading in response to a scathing report from a hedge fund that has a short positions on the stock. The overblown reaction is a good indicator of market climate.

The biotech's shares dipped precipitously in morning trading, but recovered slightly as the trading day went on. Shares were down...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

J&J Secures Another Indication On Caplyta’s Path To $5bn In Sales

 
• By Mandy Jackson

The US FDA approved Caplyta (lumateperone) as an adjunctive treatment for major depressive disorder, the third indication for a drug J&J expects to deliver $5bn in peak sales.

Five Things To Know About AbbVie’s Q3 Sales And Earnings Report

 
• By Joseph Haas

AbbVie stressed its continued revenue growth driven by Skyrizi and Rinvoq, while trying to sound unconcerned about unsettled drug-pricing policies such as MFN negotiations.

Novartis Still Has Significant M&A Firepower After Avidity Acquisition

 
• By Kevin Grogan

The Basel-based company has faith in its existing rare disease commercial platform to successfully market the newly-acquired assets.

Alkermes To Buy Avadel, Jumpstarting A Move Into Commercial Sleep Market

 
• By Jessica Merrill

The company will gain Lumryz, an oxybate for narcolepsy, paving the commercial path ahead of the eventual launch of its own Phase III-ready asset alixorexton.

More from Therapy Areas

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.